WTF with PTX: Changing the game for T-Cell Lymphoma

What is Relapsed or Refractory T-Cell Lymphoma? Why is it so difficult to treat? What therapies currently exist? And what changes can the healthcare sector make in this area?

Tylah Tully is joined in this episode by Prescient Therapeutics (ASX:PTX) CEO James McDonnell to answer these questions and more.

This video was developed in collaboration with Prescient Therapeutics, a Stockhead advertiser at the time of publishing.

This video does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.